\-\ Texto\\:\\ \ \(0\)\
\-\ left\\ lateral\\ hepatic\\ lobe\\ mass\\ shows\\ peripheral\\ nodular\\ enhancement\\ on\\ arterial\\ phase\\ imaging\\.\\ \\ on\\ delayed\\ imaging\\,\\ continual\\ filling\\ in\\ of\\ this\\ mass\\ with\\ contrast\\ is\\ seen\\.\ \(0\)\
\-\ cavernous\\ hemangioma\ \(14\)\
\-\ ddx\\ for\\ enhancing\\ focal\\ liver\\ lesions\\:\ \(0\)\
\-\ cavernous\\ hemangioma\ \(14\)\
\-\ focal\\ nodular\\ hyperplasia\ \(9\)\
\-\ adenoma\ \(519\)\
\-\ hepatocellular\\ carcinoma\ \(28\)\
\-\ metastases\ \(207\)\
\-\ 30\\ year\\ old\\ male\\ presents\\ with\\ hematuria\\.\ \(1\)\
\-\ diagnosis\\ of\\ hepatic\\ hemangioma\\ can\\ be\\ made\\ on\\ the\\ basis\\ of\\ a\\ characteristic\\ peripheral\\ nodular\\ enhancement\\ with\\ gradual\\ fill\\-in\\,\\ mirroring\\ the\\ density\\ of\\ the\\ blood\\ pool\\.\\ focal\\ nodular\\ hyperplasia\\ is\\ the\\ second\\ most\\ common\\ benign\\ hepatic\\ neoplasm\\.\\ \\ fnh\\ is\\ a\\ hypervascular\\,\\ well\\-marginated\\ tumor\\ that\\ often\\ contains\\ a\\ characteristic\\ stellate\\ central\\ scar\\.\\ \\ most\\ often\\,\\ fnh\\ shows\\ intense\\ early\\ arterial\\ phase\\ enhancement\\,\\ but\\ is\\ often\\ imperceptible\\ during\\ later\\ phases\\ as\\ the\\ tumor\\ parenchymal\\ attenuation\\ matches\\ normal\\ enhancing\\ hepatic\\ parenchyma\\.\\ \ \(0\)\
\-\ adenomas\\ are\\ also\\ hypervascular\\ lesions\\ that\\ can\\ have\\ a\\ variable\\ appearance\\ on\\ ct\\ due\\ to\\ its\\ propensity\\ to\\ hemorrhage\\.\\ \\ typically\\,\\ areas\\ of\\ infarction\\ and\\ hemorrhage\\ are\\ present\\ and\\ may\\ make\\ them\\ difficult\\ to\\ distinguish\\ from\\ hepatocellular\\ carcinoma\\.\\ hepatic\\ adenomas\\ also\\ tend\\ to\\ enhance\\ early\\ during\\ arterial\\ phase\\ in\\ a\\ heterogenous\\ fashion\\.\ \(0\)\
\-\ while\\ both\\ are\\ variable\\ in\\ their\\ phase\\ of\\ enhancement\\ and\\ washout\\ characteristics\\,\\ neither\\ hepatocellular\\ carcinoma\\ nor\\ metastases\\ will\\ demonstrate\\ the\\ specific\\ enhancement\\ pattern\\ described\\ above\\ and\\ demonstrated\\ in\\ this\\ case\\ and\\ should\\ not\\ be\\ realistically\\ considered\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ hepatic\\:\\ 0\\.2807215882690762\ \(0\)\
\-\ phase\\:\\ 0\\.2413130684483305\ \(0\)\
\-\ nodular\\:\\ 0\\.22457727061526095\ \(0\)\
\-\ hepatocellular\\:\\ 0\\.2174409973915953\ \(0\)\
\-\ enhancement\\:\\ 0\\.20289892905490428\ \(0\)\
\-\ hemangioma\\:\\ 0\\.17791452520499976\ \(0\)\
\-\ fnh\\:\\ 0\\.17739615056777688\ \(0\)\
\-\ arterial\\:\\ 0\\.1741802538352606\ \(0\)\
\-\ adenomas\\:\\ 0\\.1640728807895219\ \(0\)\
\-\ hypervascular\\:\\ 0\\.14909001759421558\ \(0\)\
\-\ often\\:\\ 0\\.13800786221028624\ \(0\)\
\-\ variable\\:\\ 0\\.13691666013923134\ \(0\)\
\-\ hyperplasia\\:\\ 0\\.12855052187352412\ \(0\)\
\-\ focal\\:\\ 0\\.1265135223965399\ \(0\)\
\-\ carcinoma\\:\\ 0\\.1265135223965399\ \(0\)\
\-\ cavernous\\:\\ 0\\.12231118835510113\ \(0\)\
\-\ metastases\\:\\ 0\\.11399404645287466\ \(0\)\
\-\ characteristic\\:\\ 0\\.11399404645287466\ \(0\)\
\-\ mirroring\\:\\ 0\\.11274821832272619\ \(0\)\
\-\ realistically\\:\\ 0\\.11274821832272619\ \(0\)\
\-\ matches\\:\\ 0\\.10418138452131621\ \(0\)\
\-\ early\\:\\ 0\\.10164026004144375\ \(0\)\
\-\ continual\\:\\ 0\\.10142348003641165\ \(0\)\
\-\ peripheral\\:\\ 0\\.1008297396487176\ \(0\)\
\-\ imperceptible\\:\\ 0\\.09917010799758091\ \(0\)\
\-\ propensity\\:\\ 0\\.09561455071990624\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.09440586015679918\ \(0\)\
\-\ stellate\\:\\ 0\\.09060327419617094\ \(0\)\
\-\ during\\:\\ 0\\.08931175451433429\ \(0\)\
\-\ enhancing\\:\\ 0\\.08833072666658916\ \(0\)\
\-\ in\\:\\ 0\\.08769318137230342\ \(0\)\
\-\ on\\:\\ 0\\.08517138651513334\ \(0\)\
\-\ the\\:\\ 0\\.08440635045824503\ \(0\)\
\-\ washout\\:\\ 0\\.0842898124335917\ \(0\)\
\-\ of\\:\\ 0\\.08278170233976434\ \(0\)\
\-\ shows\\:\\ 0\\.08275727602911404\ \(0\)\
\-\ neither\\:\\ 0\\.08203644039476095\ \(0\)\
\-\ fashion\\:\\ 0\\.08153190794868712\ \(0\)\
\-\ phases\\:\\ 0\\.08104716626527508\ \(0\)\
\-\ lesions\\:\\ 0\\.08098032023976236\ \(0\)\
\-\ are\\:\\ 0\\.0802570301930171\ \(0\)\
\-\ gradual\\:\\ 0\\.07969753632847001\ \(0\)\
\-\ is\\:\\ 0\\.07722992457532832\ \(0\)\
\-\ them\\:\\ 0\\.07668653094459713\ \(0\)\
\-\ distinguish\\:\\ 0\\.07635692931461825\ \(0\)\
\-\ basis\\:\\ 0\\.0754177945181622\ \(0\)\
\-\ imaging\\:\\ 0\\.0741024869401082\ \(0\)\
\-\ pool\\:\\ 0\\.07399561485480476\ \(0\)\
\-\ can\\:\\ 0\\.07399454503371936\ \(0\)\
\-\ tumor\\:\\ 0\\.07375338548885356\ \(0\)\
\-\ most\\:\\ 0\\.07338286334584934\ \(0\)\
\-\ and\\:\\ 0\\.07284198685326267\ \(0\)\
\-\ tend\\:\\ 0\\.07201388734729035\ \(0\)\
\-\ to\\:\\ 0\\.07050155359864152\ \(0\)\
\-\ contains\\:\\ 0\\.06863119063063983\ \(0\)\
\-\ nor\\:\\ 0\\.06863119063063983\ \(0\)\
\-\ make\\:\\ 0\\.06845833006961567\ \(0\)\
\-\ ddx\\:\\ 0\\.06700261082355503\ \(0\)\
\-\ scar\\:\\ 0\\.06655313115733318\ \(0\)\
\-\ intense\\:\\ 0\\.06655313115733318\ \(0\)\
\-\ heterogenous\\:\\ 0\\.06640686520598098\ \(0\)\
\-\ also\\:\\ 0\\.06632434169817622\ \(0\)\
\-\ characteristics\\:\\ 0\\.0646479322450507\ \(0\)\
\-\ parenchymal\\:\\ 0\\.06333314187646404\ \(0\)\
\-\ enhance\\:\\ 0\\.06310842061945184\ \(0\)\
\-\ hematuria\\:\\ 0\\.06235259300582372\ \(0\)\
\-\ that\\:\\ 0\\.061190541474066794\ \(0\)\
\-\ difficult\\:\\ 0\\.05851230561737696\ \(0\)\
\-\ their\\:\\ 0\\.05851230561737696\ \(0\)\
\-\ parenchyma\\:\\ 0\\.05727168627740266\ \(0\)\
\-\ described\\:\\ 0\\.05720244615994346\ \(0\)\
\-\ be\\:\\ 0\\.05719977302279723\ \(0\)\
\-\ adenoma\\:\\ 0\\.05620786189991773\ \(0\)\
\-\ infarction\\:\\ 0\\.05534666486104515\ \(0\)\
\-\ delayed\\:\\ 0\\.05516967861028031\ \(0\)\
\-\ considered\\:\\ 0\\.054937571720430095\ \(0\)\
\-\ filling\\:\\ 0\\.05459738523625439\ \(0\)\
\-\ made\\:\\ 0\\.054375687298396556\ \(0\)\
\-\ attenuation\\:\\ 0\\.05394387643953188\ \(0\)\
\-\ mass\\:\\ 0\\.05385984602705771\ \(0\)\
\-\ specific\\:\\ 0\\.05342450049840976\ \(0\)\
\-\ second\\:\\ 0\\.052780381712856365\ \(0\)\
\-\ pattern\\:\\ 0\\.05263638790575937\ \(0\)\
\-\ its\\:\\ 0\\.05216817552977766\ \(0\)\
\-\ above\\:\\ 0\\.05086139659876361\ \(0\)\
\-\ later\\:\\ 0\\.05045480306957206\ \(0\)\
\-\ typically\\:\\ 0\\.04949325081034355\ \(0\)\
\-\ liver\\:\\ 0\\.04863561235853349\ \(0\)\
\-\ this\\:\\ 0\\.04845158758492973\ \(0\)\
\-\ benign\\:\\ 0\\.04843018942502735\ \(0\)\
\-\ neoplasm\\:\\ 0\\.0481283183598526\ \(0\)\
\-\ 30\\:\\ 0\\.048095227768087105\ \(0\)\
\-\ areas\\:\\ 0\\.0478660415969548\ \(0\)\
\-\ central\\:\\ 0\\.04708055948822228\ \(0\)\
\-\ density\\:\\ 0\\.04675015678693734\ \(0\)\
\-\ should\\:\\ 0\\.046002620736762076\ \(0\)\
\-\ while\\:\\ 0\\.045564106318269654\ \(0\)\
\-\ will\\:\\ 0\\.0453770426381219\ \(0\)\
\-\ demonstrated\\:\\ 0\\.04332869842306872\ \(0\)\
\-\ appearance\\:\\ 0\\.04250298811849543\ \(0\)\
\-\ with\\:\\ 0\\.04141558219359328\ \(0\)\
\-\ blood\\:\\ 0\\.040944932860548566\ \(0\)\
\-\ lobe\\:\\ 0\\.04074276833069726\ \(0\)\
\-\ due\\:\\ 0\\.04052593244193494\ \(0\)\
\-\ common\\:\\ 0\\.0399827703558796\ \(0\)\
\-\ both\\:\\ 0\\.03931543803903471\ \(0\)\
\-\ demonstrate\\:\\ 0\\.036652091601593786\ \(0\)\
\-\ diagnosis\\:\\ 0\\.03654779285063782\ \(0\)\
\-\ present\\:\\ 0\\.03617692122617347\ \(0\)\
\-\ may\\:\\ 0\\.03547888359614588\ \(0\)\
\-\ case\\:\\ 0\\.035419492186128325\ \(0\)\
\-\ have\\:\\ 0\\.03521966987165208\ \(0\)\
\-\ lateral\\:\\ 0\\.034988647656745864\ \(0\)\
\-\ but\\:\\ 0\\.034863402351834355\ \(0\)\
\-\ contrast\\:\\ 0\\.034255534585785875\ \(0\)\
\-\ presents\\:\\ 0\\.033915152903975385\ \(0\)\
\-\ seen\\:\\ 0\\.033191821391836976\ \(0\)\
\-\ male\\:\\ 0\\.03139025037555031\ \(0\)\
\-\ normal\\:\\ 0\\.028785537775853274\ \(0\)\
\-\ as\\:\\ 0\\.02832319874856592\ \(0\)\
\-\ from\\:\\ 0\\.028000448139165926\ \(0\)\
\-\ not\\:\\ 0\\.02783255499067519\ \(0\)\
\-\ ct\\:\\ 0\\.026840814273949513\ \(0\)\
\-\ left\\:\\ 0\\.024049806535855558\ \(0\)\
\-\ year\\:\\ 0\\.021727361478395598\ \(0\)\
\-\ for\\:\\ 0\\.02136864771668729\ \(0\)\
\-\ old\\:\\ 0\\.020865788132083785\ \(0\)\
